한빛사 논문
Donghee Kim 1,*, Clark Andrew Bonham 2, Peter Konyn 3, George Cholankeril 4, Aijaz Ahmed 5
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
2Department of Surgery, Stanford University School of Medicine, Stanford, California.
3Department of Medicine, Stanford University School of Medicine, Stanford, California.
4Liver Center, Division of Abdominal Transplantation, Michael E DeBakey Department of General Surgery, Baylor College of Medicine, Houston, Texas; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
5Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
*Corresponding author.
Abstract
Chronic liver disease (CLD) and cirrhosis accounts for approximately 2 million deaths annually worldwide. CLD and cirrhosis-related mortality has increased steadily in the United States.1,2 With the global pandemic of coronavirus disease 2019 (COVID-19), patients with CLD and cirrhosis represent a vulnerable population at higher risk for complications and mortality.3,4 Although high mortality from COVID-19 among patients with CLD and cirrhosis have been reported,5 national trends in mortality related to CLD and cirrhosis before and during the COVID-19 pandemic have not been assessed. This study estimated the temporal quarterly trends in CLD and cirrhosis-related mortality in the United States from 2017 Q1 to 2020 Q3 using provisional data releases from the National Vital Statistics System.6,7.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기